title: Hemodialysis: an appropriate therapy in myeloma-induced renal failure.
abstract: To determine whether vigorous treatment with dialysis is of benefit to patients with myeloma-induced renal failure at presentation, we retrospectively reviewed outcomes in a group of patients diagnosed with multiple myeloma between January 1986 and September 1993. Increased age (P = 0.003), presence of renal impairment (P = 0.006), and failure to enter plateau phase (P < 0.001) were independently associated with shortened survival. However, there was no difference in outcome between patients with severe renal failure, those treated with dialysis, and those with milder renal impairment (median survival, 22 months in both groups), nor was reversibility of renal failure associated with any survival advantage. The lack of correlation between severity or reversibility of the renal failure and survival suggests that there may be characteristics of some patients or their underlying myeloma that are responsible both for renal impairment and for adverse prognosis. In this study, neither age, clinical stage, labeling index, nor response to treatment was able to account for the difference in outcome between patients with and without renal failure. The prolongation of life achieved in the dialysis patients such that their median survival was identical with that of the group with milder renal impairment was considered to represent a significant benefit to these patients and to justify the offer of dialysis to all patients requiring it.
authors.affiliation: Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, Sydney, Australia. a.sharland@centenary.usyd.edu.au
authors.forename: A
authors.initials: A
authors.lastname: Sharland
authors.forename: L
authors.initials: L
authors.lastname: Snowdon
authors.forename: D E
authors.initials: DE
authors.lastname: Joshua
authors.forename: J
authors.initials: J
authors.lastname: Gibson
authors.forename: D J
authors.initials: DJ
authors.lastname: Tiller
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000209:etiology / Q000628:therapy / Q000652:urine; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000150:complications; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001536:Bence Jones Protein / Q000652:urine; D002423:Cause of Death; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D007147:Immunoglobulin Light Chains / Q000652:urine; D007674:Kidney Diseases / Q000150:complications; D007676:Kidney Failure, Chronic / Q000097:blood / Q000209:etiology / Q000628:therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis; D012044:Regression Analysis; D006435:Renal Dialysis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007147:Immunoglobulin Light Chains; D001536:Bence Jones Protein; D003404:Creatinine